Apogee Therapeutics, Inc. (APGE) on Tuesday reported positive interim data from a Phase 1b trial of zumilokibart in patients with mild-to-moderate asthma.
Results showed rapid and durable suppression of fractional exhaled nitric oxide (FeNO)—a key Type 2 inflammation biomarker—through 16 weeks in all patients, with suppression maintained through 32 weeks in those with available follow-up.
Apogee said Phase 2 APEX Part A maintenance data are expected in the first quarter of 2026, followed by Phase 2 Part B induction data in the second quarter of 2026. The company plans to initiate a Phase 3 trial in atopic dermatitis in the second half of 2026, supporting a potential launch in 2029.
Additionally, a Phase 1b head-to-head trial of APG279 versus Dupixent in moderate-to-severe atopic dermatitis remains on track, with results expected in the second half of 2026.
As of September 30, 2025, Apogee had total cash of $913 million, providing a cash runway into the second half of 2028.
Apogee shares were up more than 1% in pre-market trading after closing at $77.51, up 2.28% on Monday.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.